Amgen Inc

Valeant partners with AstraZeneca for psoriasis drug

Valeant Pharmaceuticals, Inc. of Canada has partnered with AstraZeneca for the selling rights of psoriasis drug brodalumab. Amgen Inc. ended its partnership with AstraZeneca due to its worries over the drug's side effects.

Read Full Article

Amgen's new leukemia drug to carry $178,000 price tag

Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available on Thursday, which would make it one of the world's most expensive cancer drugs.

Read Full Article

Pfizer beats sales and profit forecasts, mum on future deals

Pfizer Inc (PFE.N) reported stronger-than-expected quarterly results, helped by growing sales of its cancer drugs and demand for its medicines in emerging markets, but did not signal any acquisition plans following its recent failed efforts to buy rival British drugmaker AstraZeneca Plc (AZN.L).

Read Full Article

Despite Third Point, low expectations for Amgen breakup

Amgen Inc (AMGN.O), one of the world's largest biotechnology companies, will unveil next week its first strategy update since early 2013, but few expect a major shift like the split-up recently proposed by Daniel Loeb's Third Point hedge fund.

Read Full Article

Onyx undervalued during buyout, according to its shareholders

The buyout of Onyx Pharmaceuticals was tainted with conflicts of interest and undervaluation, according to its shareholders.

Read Full Article

Bradway’s business savvy leads to successful Onyx acquisition

As Amgen Inc's acquisition of Onyx Pharmeceuticals Inc comes to a close, Amgen Chief Executive Officer Robert Bradway is lauded for being a great dealmaker.

Read Full Article

Amgen on buyout streak after Onyx buyout

Amgen was looking into buying more small-sized but profitable firms after its successful bid with Onyx Pharmaceuticals.

Read Full Article

Amgen nearing acquisition of Onyx for USD125 a share

Amgen Inc. might announced the agreement to acquire Onyx Pharmaceuticals Inc. for USD 125 per share piece as soon as Monday.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics